FREMONT, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX) today announced that it will present at the Merrill
Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, February 10, 2005 at 7:30 a.m. PT / 10:30
a.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of
the webcast will also be available on the company's website until Thursday, February 24, 2005.
Bill Ringo, president and chief executive officer of Abgenix, will provide an update on the company's antibody drug development
activities.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic
antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing
capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a
variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product
portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more
information on Abgenix, visit the company's website at www.abgenix.com.
SOURCE Abgenix, Inc. |
